Wells Fargo Sees Amphastar Pharmaceuticals, Inc.'s (AMPH) AMP-007 as Key to Mid- to High-Single-Digit Growth [Yahoo! Finance]
Amphastar Pharmaceuticals, Inc. (AMPH)
Last amphastar pharmaceuticals, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amphastar.com/investor-relations
Company Research
Source: Yahoo! Finance
Wells Fargo Sees Amphastar Pharmaceuticals, Inc.'s (AMPH) AMP-007 as Key to Mid- to High-Single-Digit Growth The seventh stock among the small-cap stocks is Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). TheFly reported on February 27 that Wells Fargo reduced its price target on AMPH to $30 from $34 and kept an Overweight rating on the shares. Despite the recent approvals of AMP-015 and AMP-007, the firm observes that the stock is under pressure because of the reduced sales projection. According to the firm, AMP-007's performance is anticipated to be crucial in attaining mid-to high-single-digit revenue growth in the future. In a recent development, the FDA approved Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)'s Abbreviated New Drug Application (ANDA) for Ipratropium Bromide HFA Inhalation Aerosol, 17 mcg per actuation, on February 26. The FDA found that AMPH's product is medically and bioequivalent to Atrovent HFA Inhalation Aerosol from Boehringer Ingelheim. For this inhal
Show less
Read more
Impact Snapshot
Event Time:
AMPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMPH alerts
High impacting Amphastar Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMPH
News
- Amphastar Pharmaceuticals Highlights Baqsimi Milestones, Primatene Growth at Needham Conference [Yahoo! Finance]Yahoo! Finance
- Amphastar Pharmaceuticals (AMPH) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c-)" to "sell (d+)".MarketBeat
- Amphastar Pharmaceuticals (AMPH) had its price target lowered by Barclays PLC from $30.00 to $23.00. They now have an "equal weight" rating on the stock.MarketBeat
- Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Amphastar Pharmaceuticals: Why I Like Bull Put Options Strategy Here [Seeking Alpha]Seeking Alpha
AMPH
Earnings
- 2/26/26 - Miss
AMPH
Sec Filings
- 4/13/26 - Form ARS
- 4/13/26 - Form DEFA14A
- 4/13/26 - Form DEF
- AMPH's page on the SEC website